Seite 1 von 8
Medivation - gute Reboundmöglichkeit!
Diskussionsstatistik
Anzahl Beiträge: 78
Aufrufe gesamt: 2.685
Aufrufe heute: 0
Diskussionsnr.: 1.156.324
Aufrufe gesamt: 2.685
Aufrufe heute: 0
Diskussionsnr.: 1.156.324
WKN: A0ETXH
ISIN: US58501N1019
Symbol: WMD
ISIN: US58501N1019
Symbol: WMD
| 70,30 |
|
+0,24 % +0,165 |
Frankfurt (EUR), 25.05.12 | 15:42
Beitrag schreiben
Ansicht
- Umgekehrte Sortierung (neuste zuerst)
- Die letzten 30 Beiträge
- 500 Beiträge pro Seite
Gustl24
schrieb am 03.03.10 16:04:05
Beitrag Nr.1
(39.050.936)
Antwort
Zitat
dramatischer absturz heute nach schlechten p3 -daten:
reuters:
7:30am EST
Pfizer and Medivation, Inc. announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints Pfizer And Medivation, Inc. Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer's Disease Clinical Development Programcompared to placebo. Co-primary endpoints were measures of cognition and global function. CONNECTION is a Phase 3, multi-national, double-blind, placebo-controlled safety and efficacy trial involving 598 patients with mild-to-moderate AD at 63 sites in North America, Europe, and South America. Patients had a mean age of 74.4 years and a mean score of 17.7 on the Mini-Mental State Examination (MMSE) upon entry into the study. More than 40% of the patients enrolled were in the United States. In the study, patients were randomized to one of three treatment groups, receiving dimebon 20 mg three times a day (TID), dimebon 5 mg TID, or placebo TID for six months. The 5 mg arm was included in the study to help define the effective dose range for dimebon treatment.
reuters:
7:30am EST
Pfizer and Medivation, Inc. announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints Pfizer And Medivation, Inc. Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer's Disease Clinical Development Programcompared to placebo. Co-primary endpoints were measures of cognition and global function. CONNECTION is a Phase 3, multi-national, double-blind, placebo-controlled safety and efficacy trial involving 598 patients with mild-to-moderate AD at 63 sites in North America, Europe, and South America. Patients had a mean age of 74.4 years and a mean score of 17.7 on the Mini-Mental State Examination (MMSE) upon entry into the study. More than 40% of the patients enrolled were in the United States. In the study, patients were randomized to one of three treatment groups, receiving dimebon 20 mg three times a day (TID), dimebon 5 mg TID, or placebo TID for six months. The 5 mg arm was included in the study to help define the effective dose range for dimebon treatment.
Gustl24
schrieb am 03.03.10 16:09:08
Beitrag Nr.2
(39.051.015)
Antwort
Zitat
nach bekanntgabe der daten z.zt. ca. 68% im minus...
das erscheint mir sehr übertrieben, da Medivation
rel. breit aufgestellt ist und mit verschiedenen
big playern im pharmabereich über sehr gute
partnerschaften verfügt.
als beispiel sei genannt:
partnerschaft mit astellas - prostata cancer:
Astellas Pharma Inc. and Medivation, Inc. Enter Into Worldwide Agreement To Co-Develop and Co-Commercialize MDV3100 For Treatment Of Prostate Cancer
Tuesday, 27 Oct 2009 07:30am EDT
Astellas Pharma Inc. and Medivation, Inc. announced that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. Under the terms of the agreement, Medivation will receive an up-front cash payment of $110 million. Medivation is also eligible to receive payments of up to $335 million upon the attainment of development and regulatory milestones plus up to an additional $320 million in commercial milestone payments. The companies will collaborate on a comprehensive development program that will include additional studies to develop MDV3100 for both late- and early-stage prostate cancer. Subject to receipt of regulatory approval, the companies will jointly commercialize MDV3100 in the U.S. The companies will share equally all U.S. development costs, commercialization costs, and profits. Astellas will have responsibility for developing and commercializing MDV3100 outside the U.S. and will pay Medivation tiered double-digit royalties on ex-U.S. sales.
das erscheint mir sehr übertrieben, da Medivation
rel. breit aufgestellt ist und mit verschiedenen
big playern im pharmabereich über sehr gute
partnerschaften verfügt.
als beispiel sei genannt:
partnerschaft mit astellas - prostata cancer:
Astellas Pharma Inc. and Medivation, Inc. Enter Into Worldwide Agreement To Co-Develop and Co-Commercialize MDV3100 For Treatment Of Prostate Cancer
Tuesday, 27 Oct 2009 07:30am EDT
Astellas Pharma Inc. and Medivation, Inc. announced that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. Under the terms of the agreement, Medivation will receive an up-front cash payment of $110 million. Medivation is also eligible to receive payments of up to $335 million upon the attainment of development and regulatory milestones plus up to an additional $320 million in commercial milestone payments. The companies will collaborate on a comprehensive development program that will include additional studies to develop MDV3100 for both late- and early-stage prostate cancer. Subject to receipt of regulatory approval, the companies will jointly commercialize MDV3100 in the U.S. The companies will share equally all U.S. development costs, commercialization costs, and profits. Astellas will have responsibility for developing and commercializing MDV3100 outside the U.S. and will pay Medivation tiered double-digit royalties on ex-U.S. sales.
Gustl24
schrieb am 03.03.10 16:12:59
Beitrag Nr.3
(39.051.067)
Antwort
Zitat
darüberhinaus sind versch p3-studien bzgl. alzheimer
in der durchführung bzw. finalen phase:
Pfizer And Medivation, Inc. Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer`s Disease
Tuesday, 3 Nov 2009 08:00am EST
Pfizer and Medivation, Inc. announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with moderate-to-severe Alzheimer`s disease (AD). The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil HCI tablets, the leading AD medication worldwide, on neuropsychiatric symptoms and activities of daily living. The CONSTELLATION study will evaluate as primary endpoints the effects of adding dimebon to memantine HCI, another standard of care, on cognition, memory and activities of daily living.
in der durchführung bzw. finalen phase:
Pfizer And Medivation, Inc. Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer`s Disease
Tuesday, 3 Nov 2009 08:00am EST
Pfizer and Medivation, Inc. announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with moderate-to-severe Alzheimer`s disease (AD). The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil HCI tablets, the leading AD medication worldwide, on neuropsychiatric symptoms and activities of daily living. The CONSTELLATION study will evaluate as primary endpoints the effects of adding dimebon to memantine HCI, another standard of care, on cognition, memory and activities of daily living.
coldor
schrieb am 03.03.10 16:52:17
Beitrag Nr.4
(39.051.549)
Antwort
Zitat
Hab diesen aktuellen Bericht dazu gefunden:
BOSTON (MarketWatch) -- Shares of Medivation Inc. got crushed Wednesday, plunging as a late-stage clinical study showed its drug candidate for treating Alzheimer's disease proved largely ineffective.
San Francisco-based Medivation /quotes/comstock/15*!mdvn/quotes/nls/mdvn (MDVN 12.93, -27.32, -67.88%) and blue-chip partner Pfizer Inc. /quotes/comstock/13*!pfe/quotes/nls/pfe (PFE 17.52, -0.08, -0.46%) said that a Phase III trial of the candidate, known as dimebon, failed to show the drug's effectiveness in improving cognition in patients with mild-to-moderate Alzheimer's disease.
Shares of Medivation plummeted nearly 70% to $13.02 in early action. Pfizer, which entered into a co-development deal for dimebon in 2008, saw its shares traded down 1% at $17.46.
In a statement, the companies said the results were unexpected and disappointing.
"We are evaluating the [study] data with Medivation. After that review, Pfizer will be in a position to determine appropriate next steps regarding the dimebon program," said Briggs Morrison, a senior vice president for clinical development at Pfizer.
"We recognize the significant medical need, and we are committed to advancing treatment options for Alzheimer's disease," Briggs added.
Advisers Team Up with Career Counselors
Jobs are increasingly on the minds of financial advisory clients, says Shelly Banjo in a 60-second seminar on how financial advisers can team up with career counselors to help their clients.
Dimebon is also in late-stage testing for the treatment of the equally devastating Huntington's disease.
Alzheimer's is a degenerative neurological disease that afflicts about 5.3 million Americans. About 13% of all people aged 65 and over are believed to be afflicted, with that number rocketing to about 50% at age 85, according to the Alzheimer's Association.
To date, four drugs have been approved to treat Alzheimer's in the U.S. While the drugs can help boost memory, they generally lose their effectiveness after 18 months of use.
Originally approved over 25 years ago in Russia as an antihistamine, dimebon is being tested as a treatment for Alzheimer's and for Huntington's disease. Medivation began testing the drug for Alzheimer's after early studies indicated it might inhibit the death of neurons in the brain.
Kann´s aber nicht richtig einordnen, ob der Absturz übertrieben ist, oder nicht.
BOSTON (MarketWatch) -- Shares of Medivation Inc. got crushed Wednesday, plunging as a late-stage clinical study showed its drug candidate for treating Alzheimer's disease proved largely ineffective.
San Francisco-based Medivation /quotes/comstock/15*!mdvn/quotes/nls/mdvn (MDVN 12.93, -27.32, -67.88%) and blue-chip partner Pfizer Inc. /quotes/comstock/13*!pfe/quotes/nls/pfe (PFE 17.52, -0.08, -0.46%) said that a Phase III trial of the candidate, known as dimebon, failed to show the drug's effectiveness in improving cognition in patients with mild-to-moderate Alzheimer's disease.
Shares of Medivation plummeted nearly 70% to $13.02 in early action. Pfizer, which entered into a co-development deal for dimebon in 2008, saw its shares traded down 1% at $17.46.
In a statement, the companies said the results were unexpected and disappointing.
"We are evaluating the [study] data with Medivation. After that review, Pfizer will be in a position to determine appropriate next steps regarding the dimebon program," said Briggs Morrison, a senior vice president for clinical development at Pfizer.
"We recognize the significant medical need, and we are committed to advancing treatment options for Alzheimer's disease," Briggs added.
Advisers Team Up with Career Counselors
Jobs are increasingly on the minds of financial advisory clients, says Shelly Banjo in a 60-second seminar on how financial advisers can team up with career counselors to help their clients.
Dimebon is also in late-stage testing for the treatment of the equally devastating Huntington's disease.
Alzheimer's is a degenerative neurological disease that afflicts about 5.3 million Americans. About 13% of all people aged 65 and over are believed to be afflicted, with that number rocketing to about 50% at age 85, according to the Alzheimer's Association.
To date, four drugs have been approved to treat Alzheimer's in the U.S. While the drugs can help boost memory, they generally lose their effectiveness after 18 months of use.
Originally approved over 25 years ago in Russia as an antihistamine, dimebon is being tested as a treatment for Alzheimer's and for Huntington's disease. Medivation began testing the drug for Alzheimer's after early studies indicated it might inhibit the death of neurons in the brain.
Kann´s aber nicht richtig einordnen, ob der Absturz übertrieben ist, oder nicht.
Gustl24
schrieb am 03.03.10 16:59:48
Beitrag Nr.5
(39.051.630)
Antwort
Zitat
Antwort auf Beitrag Nr.:
39.051.549 von coldor am 03.03.10
16:52:17betreffend Dimebon - alzheimer ist diese
auswertung sicherlich
entscheident:
"We are evaluating the [study] data with Medivation. After that review, Pfizer will be in a position to determine appropriate next steps regarding the dimebon program," said Briggs Morrison, a senior vice president for clinical development at Pfizer.
da jedoch sehr vielversprechende weitere late-stage entwicklungen
im bereich huntington´s disease und pr. cancer laufen
erscheint mir dieser "brutale" kurseinbruch übertrieben...
30-40% abschlag sollten IMO ausreichen...
die nächsten stellungnahmen sollten licht ins dunkel bringen
entscheident:
"We are evaluating the [study] data with Medivation. After that review, Pfizer will be in a position to determine appropriate next steps regarding the dimebon program," said Briggs Morrison, a senior vice president for clinical development at Pfizer.
da jedoch sehr vielversprechende weitere late-stage entwicklungen
im bereich huntington´s disease und pr. cancer laufen
erscheint mir dieser "brutale" kurseinbruch übertrieben...
30-40% abschlag sollten IMO ausreichen...
die nächsten stellungnahmen sollten licht ins dunkel bringen
tradepunk
schrieb am 03.03.10 17:01:04
Beitrag Nr.6
(39.051.643)
Antwort
Zitat
Antwort auf Beitrag Nr.:
39.051.549 von coldor am 03.03.10
16:52:17Scheint zumindest erstmal beendet zu sein!
tradepunk
schrieb am 03.03.10 17:03:52
Beitrag Nr.7
(39.051.667)
Antwort
Zitat
Antwort auf Beitrag Nr.:
39.051.630 von Gustl24 am 03.03.10
16:59:48"30-40% abschlag sollten IMO
ausreichen..."
30% Abschlag auf gestern, wären 100% + auf Jetzt!
30% Abschlag auf gestern, wären 100% + auf Jetzt!
Gustl24
schrieb am 03.03.10 17:31:46
Beitrag Nr.8
(39.051.945)
Antwort
Zitat
Antwort auf Beitrag Nr.:
39.051.667 von tradepunk am 03.03.10
17:03:52sicherlich war p3 für alzheimer ein grosser
hoffnungsträger für
medivation...die niedergeschlagenheit bei medivation und pfizer
muss im conference call recht hoch sein - gewesen sein!
aber kurse um 15-16 dollar sehe ich ende der woche als realistisch an...
positive überraschungen nach auswertungen bzw.
der anderen p3 studien hunt.disease und prost.cancer in bälde
könnten den kurs mittelfristig wieder über 20 dollar bringen...
die alten kursziele im bereich 50 dollar sind natürlich
vorerst geschichte...bin auf die ersten neubewertungen gespannt.
rodman&r. hat auf neutral glaube ich heute abgestuft - noch keine
kursbewertung bekannt...
medivation...die niedergeschlagenheit bei medivation und pfizer
muss im conference call recht hoch sein - gewesen sein!
aber kurse um 15-16 dollar sehe ich ende der woche als realistisch an...
positive überraschungen nach auswertungen bzw.
der anderen p3 studien hunt.disease und prost.cancer in bälde
könnten den kurs mittelfristig wieder über 20 dollar bringen...
die alten kursziele im bereich 50 dollar sind natürlich
vorerst geschichte...bin auf die ersten neubewertungen gespannt.
rodman&r. hat auf neutral glaube ich heute abgestuft - noch keine
kursbewertung bekannt...
tradepunk
schrieb am 03.03.10 17:34:24
Beitrag Nr.9
(39.051.977)
Antwort
Zitat
Antwort auf Beitrag Nr.:
39.051.945 von Gustl24 am 03.03.10
17:31:46Bist Du mit der Gecshichte schon länger befasst?
Ich setzt grad einfach ein bisschen auf rebound...
ooy
schrieb am 03.03.10 17:37:35
Beitrag Nr.10
(39.052.010)
Antwort
Zitat
Antwort auf Beitrag Nr.:
39.051.945 von Gustl24 am 03.03.10
17:31:46Date Research Firm Action From To
3-Mar-10 Roth Capital Downgrade Buy Hold
3-Mar-10 Hapoalim Downgrade Outperform Neutral
3-Mar-10 Roth Capital Downgrade Buy Hold
3-Mar-10 Hapoalim Downgrade Outperform Neutral
[ Seite: 1, 2, 3 … 6, 7, 8, neuster Beitrag ]
Geben Sie Ihre Bewertung zu dieser Seite: sehr gut
1
2
3
4
5
6 schlecht
Problem melden?
Impressum | Werben | Jobs | Allgemeine Nutzungsbestimmungen | Disclaimer | Archiv | Sitemap | Hilfe | Kontakt | RSS |
wallstreet:online AG | Börsen- & Finanzwidgets für Ihre Homepage |
Kurse:
Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min.
Alle Angaben ohne Gewähr. Copyright © 1998-2012 wallstreet:online AG - Alle Rechte vorbehalten.